蜜桃传媒

Dr. Rachel Freedman is a medical oncologist and clinical researcher at DFCI in the Breast Oncology Program.  In addition to seeing patients with breast cancer, her research focuses on improving the care of vulnerable patient populations who are under-represented in clinical trials and who are at risk for worse breast cancer outcomes, including older women and those who face challenges in access to care.  In addition, she is interested in novel therapeutics, serving as the Principal Investigator for several clinical trials.  She is also the founder and Director of the Program for Older Adults with Breast Cancer at DFCI.  Dr. Freedman joined the faculty at DFCI in 2009.  She studied at Georgetown University School of Medicine and obtained her master's in public health at the Harvard University T.H. Chan School of Public Health.  Her research has been funded by Susan G Komen, ACS, NCI, Gateway for Cancer Research, METAvivor, and the Alliance for Clinical Trials Foundation.

Dr. Garrido-Castro is a medical oncologist specialized in breast cancer at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School.  Since joining the Breast Oncology Center at Dana-Farber in 2016, Dr. Garrido-Castro has established an active clinical practice and research efforts focused on the development of novel therapies to improve outcomes in patients with breast cancer.  Dr. Garrido-Castro is Co-Director of the Triple-Negative Breast Cancer (TNBC) Working Group at Dana-Farber and leads clinical trials studying immunotherapy and targeted therapy approaches for patients with breast cancer.

Dr. Tolaney received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital, where she serves as Chief of the Division of Breast Oncology.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy. 




 

Gilbert Youssef, MD is Neuro-Oncologist at Dana-Farber Cancer Institute.  He primarily treats patients with brain and spinal cord tumors, including, glioma, meningioma, ependymoma, medulloblastoma, schwannoma, lymphoma, and brain metastases.  He also treats patients who develop neurologic complications from cancer or its treatment.
He is interested in neuroimaging, while focusing on clinical endpoints in clinical trials.  He is also involved in multiple clinical trials that are ongoing at Dana-Farber.

Dr. Wen graduated from the Medical College of St. Bartholomew's Hospital, University of London, in 1981. He completed his internal medicine training at the University of London postgraduate hospitals and his neurology residency in the Harvard-Longwood Neurology Training Program. His research is focused on novel treatments of brain tumors, especially targeted molecular agents. His other clinical interests include neurologic complications of cancer.




 

Dr. Kehl received his MD from the Feinberg School of Medicine at Northwestern University in 2008. He completed his residency in internal medicine at the Brigham and Women’s Hospital. He received his fellowship training in hematology and medical oncology at the MD Anderson Cancer Center and joined the faculty in the Lowe Center for Thoracic Oncology and the Division of Population Sciences at Dana-Farber in 2017. His research focuses on the impact of healthcare delivery strategies on access to care and outcomes for patients with lung cancer, with a particular focus on analysis of population-level data.




 

Dr. Manz graduated from Duke University School of Medicine in 2012. He received his training in internal medicine at the Hospital of the University of Pennsylvania from 2012-2015, and subsequently worked as a hospitalist in oncology at the same hospital until 2017. After completing fellowship in hematology/oncology and a Masters of Science in Health Policy Research at the University of Pennsylvania, he joined Dana-Farber in GI Oncology and the Department of Population Sciences 2020.

Dr. Jänne received his MD and PhD from the University of Pennsylvania in 1996. He completed postgraduate training in internal medicine at Brigham and Women's Hospital and in medical oncology at DFCI in 2001. He is the Senior Vice President for Translational Medicine and the Scientific Director of the Belfer Center for Applied Cancer Science. His main research interests include studying the therapeutic relevance of oncogenic alterations in lung cancer. He was one of the co-discoverers of epidermal growth factor receptor (EGFR) mutations and has led the development of therapeutic strategies for patients with EGFR mutant lung cancer.




 

Dr. Shulman studies novel therapies and biomarkers for patients with advanced sarcomas. In addition to early phase clinical trials, Dr. Shulman co-leads an effort to evaluate circulating tumor DNA, a type of "liquid biopsy," as a potential tool to improve the ways in which we treat patients with bone and soft tissue sarcomas.




 

Church is a board-certified Pediatric Pathologist and Molecular Genetic Pathologist. She is the Associate Director of the Laboratory for Molecular Pediatric Pathology (LaMPP) at Boston Children’s Hospital, and an Assistant Professor at Harvard Medical School.? She has participated in several high-impact studies using molecular profiling for pediatric cancers, including the?iCat?study, Profile study, and the ongoing multi-institutional GAIN consortium study and Broad Institute's Count Me In study.? Her career is dedicated to implementing high-quality accessible molecular profiling tests to support the care of children with cancer.

Dr. Marron received his medical degree from the David Geffen School of Medicine at UCLA in 2008. He completed his residency in Pediatrics at Stanford University and his fellowship in Clinical Medical Ethics at the University of Chicago followed by his fellowship in Pediatric Hematology/Oncology at Boston Children's Hospital and the Dana-Farber Cancer Institute. Dr. Marron also received an MPH in 2016 from the Harvard T.H. Chan School of Public Health. Jonathan cares for pediatric oncology patients in the inpatient setting at Boston Children's Hospital and in the outpatient clinic at the Dana-Farber Cancer Institute. His research interests are in ethics and decision-making, health services, clinical genomics, informed consent, and medical uncertainty. Much of Dr. Marron's current work focuses on patient, parent and physician decision-making regarding pediatric precision cancer medicine. He also teaches medical ethics to medical students and graduate students through his role as teaching faculty at the Harvard Medical School Center for Bioethics.

The diagnosis of cancer is incredibly difficult for anyone, but when it’s your child, it’s particularly devastating. I make sure to reassure patients, parents, families and caregivers that this is a partnership and a journey we will weather together. Part of my job is to teach them about the tumor, the treatment, and expected side effects of that treatment, but what they don’t initially realize is how much they will teach me in return. I’ve had years of training to prepare for this; they have had but a few weeks. Yet one of the most rewarding parts of my job is to watch my patients, their families and caregivers transition from students to teachers. I think it’s important to also acknowledge that although we may not cure every patient with a brain tumor, we will help patients to live as long and as well as possible with current therapies and supportive care.




 

Dr Jennifer M. Yeh is a decision scientist whose research focuses on improving health outcomes at the population level. She is an Assistant Professor of Pediatrics at Harvard Medical School and Boston Children’s Hospital. Dr Yeh has an M.S. in Health Policy and Management from the Harvard T.H. Chan School of Public Health and a PhD in Health Policy from Harvard University. She has extensive experience applying decision-analytic modelling and cost-effectiveness analysis methods to evaluate clinical guidelines and inform health policy. Her research identifies opportunities to improve cancer control efforts spanning across the cancer continuum from prevention to survivorship. She is funded by the National Cancer Institute (NCI), the National Institute of Child Health and Human Development (NICHHD), and the American Cancer Society (ACS).

Dr. Erfani graduated from the School of Medicine at the National University of Iran, Tehran, Iran in 2014. He was offered a full scholarship to study MPH in 2013 and graduated from the School of Public Health in 2015. Seyed Hadi is currently a Post-doctoral Research Fellow in the Department of Obstetrics and Gynecology at the Baylor College of Medicine in Houston, Texas, where he is involved in multiple clinical, basic science and epidemiologic research projects related to Obstetrics and Gynecology and Maternal Fetal Medicine.

I am a breast medical oncologist and serve as the Medical Co-Director for Cancer Survivorship and Translational Behavioral Science Program at the Sylvester Comprehensive Cancer Center. I am also the Associate Director of Community Outreach of the Breast Cancer Program at Sylvester-Plantation. Since graduating from a Hematology Oncology Fellowship in 2008, I dedicated my career exclusively to building expertise in breast cancer prevention, treatment, and survivorship. Immediately after my fellowship, I joined Memorial Cancer Institute in Broward County, where I had the privilege to participate in several committees focused on patient satisfaction and quality improvement.

My goal was always to provide outstanding care that not only offers standard treatments but participation in vital clinical trials that offer patients innovative treatments before their approval. I served as a member of the local IRB for 8 years prior to 2015, when I joined University of Miami. Since joining our institution, I was invited to become a PRMC member and a member of Social Behavior committee. I value this committee and their role of making sure best research is available to our patients, not only scientifically but also ethically. I am committed to bringing new trials to our Breast Cancer Program and I am serving as a Principal Investigator on more than 10 clinical trials at the present time. I am the chair-elect for the ASCO lead TAPUR clinical trial and the local PI for TAPUR.

I have worked closely with Dr. Crane and her team on this application entitled, Comparative Effectiveness of Lifestyle Interventions for Older Cancer Survivors and Their Caregivers: the VITALITY Trial and will serve as Co-Investigator for this study. I will serve as a champion for this study for recruitment and provide my clinical oncology expertise in breast cancer to address participant related issues that may arise during this study including determining patient eligibility on a case by case basis, participate in regular research meeting, data interpretation and dissemination of findings.

Coral Olazagasti, MD is an assistant professor at the Sylvester Cancer Center, University of Miami at Miami, Florida. Dr. Olazagasti developed an interest in lung cancer screening while witnessing that the majority of new referrals during an outpatient oncology elective presented with advanced stages of lung cancer. Being a Latina physician, she is personally invested in ethnic and racial disparities in the medical field and has drawn on her own experiences to highlight the inequities and barriers that minority patients face in healthcare. She hopes to continue to expand her research passions and help close the gap for minorities and vulnerable populations.

--> Bio Coming Soon

--> Bio Coming Soon

Dr. Pongas is a board certified hematologist and oncologist with clinical experience in indolent and aggressive lymphomas. His research interest is the development of cancer therapeutics for B cell lymphomas and viral associated lymphomas. He has done significant laboratory work in Diffuse Large B cell lymphoma elucidating the therapeutic role of inhibiting various PI3K isoforms. He collaborates with clinical scientists to develop novel therapies in lymphomas and with laboratory scientists to study the mechanism of resistance to the therapies and ways to bypass it. With this approach he hopes to develop combinational therapies and increase the cure rates of various lymphomas.

Jonathan C. Trent, MD, PhD, is professor of medicine, associate director for clinical research, and director of the Bone and Soft-tissue Sarcoma Group at the Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL. He earned his undergraduate degree in chemistry at Southeastern Oklahoma State University and his MD and PhD in cancer biology from The University of Texas Health Science Center. He completed an internship and residency in internal medicine at The University of Texas Health Science Center and a fellowship in medical oncology at The University of Texas MD Anderson Cancer Center while serving as chief fellow. Prior to joining the University of Miami Miller, he held appointments as faculty of The University of Texas Graduate School of Biomedical Sciences at Houston and associate professor of medicine in the Department of Sarcoma Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston.